In this study , combined drug action from the combination of Oxa with the phytochemicals andrographolide ( Andro ) , epigallocatechin-3-gallate ( EGCG ) , chlorophyllin ( Chl ) , colchicines ( Col ) , curcumin ( Cur ) and paclitaxel ( Tax ) was evaluated in the human ovarian cancer cell lines A2780 and A2780(cisR ) .
Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. oxaliplatin (Oxa) is a third generation platinum drug currently in clinical use for the treatment against colorectal cancer. Although it has a somewhat different spectrum of activity than cisplatin (Cis), it too has two major limitations, namely problems of side-effects and drug resistance. In this study , combined drug action from the combination of Oxa with the phytochemicals andrographolide ( Andro ) , epigallocatechin-3-gallate ( EGCG ) , chlorophyllin ( Chl ) , colchicines ( Col ) , curcumin ( Cur ) and paclitaxel ( Tax ) was evaluated in the human ovarian cancer cell lines A2780 and A2780(cisR ) . The combination index (CI) was used as a measure of synergism (CI<1), addictiveness (CI=1) and antagonism (CI>1). Generally, all the combinations showed greater synergism at a lower concentration (ED(50)) than at higher concentrations (ED(75) and ED(90)). Oxa in binary combination with Col and Tax showed the highest synergism in both the cancer cell lines, when administered 4 h after the phytochemical, with CI at ED(50) ranging from 0.004 to 0.1. The combination of Oxa with the other phytochemicals generally showed greater synergism when Oxa was administered 4 h before the phytochemical. Appropriately sequenced combination of Oxa with tumor active phytochemicals produces marked synergistic effects in cisplatin resistant as well as non-resistant ovarian cancer cell lines and may offer the means of overcoming drug resistance in ovarian cancer.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. oxaliplatin (Oxa) is a third generation platinum drug currently in clinical use for the treatment against colorectal cancer. Although it has a somewhat different spectrum of activity than cisplatin (Cis), it too has two major limitations, namely problems of side-effects and drug resistance. In this study , combined drug action from the combination of Oxa with the phytochemicals andrographolide ( Andro ) , epigallocatechin-3-gallate ( EGCG ) , chlorophyllin ( Chl ) , colchicines ( Col ) , curcumin ( Cur ) and paclitaxel ( Tax ) was evaluated in the human ovarian cancer cell lines A2780 and A2780(cisR ) . The combination index (CI) was used as a measure of synergism (CI<1), addictiveness (CI=1) and antagonism (CI>1). Generally, all the combinations showed greater synergism at a lower concentration (ED(50)) than at higher concentrations (ED(75) and ED(90)). Oxa in binary combination with Col and Tax showed the highest synergism in both the cancer cell lines, when administered 4 h after the phytochemical, with CI at ED(50) ranging from 0.004 to 0.1. The combination of Oxa with the other phytochemicals generally showed greater synergism when Oxa was administered 4 h before the phytochemical. Appropriately sequenced combination of Oxa with tumor active phytochemicals produces marked synergistic effects in cisplatin resistant as well as non-resistant ovarian cancer cell lines and may offer the means of overcoming drug resistance in ovarian cancer.

            ### Response:
            curcumin, paclitaxel
            